Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives
(1) Background: Tumors of the peritoneal serosa are called peritoneal carcinosis. Their origin may be primary by primitive involvement of the peritoneum (peritoneal pseudomyxoma, peritoneal mesothelioma, etc.). This damage to the peritoneum can also be a consequence of the dissipation of cancers—in...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/10/3/225 |
| _version_ | 1797541292335431680 |
|---|---|
| author | Niki Christou Clément Auger Serge Battu Fabrice Lalloué Marie-Odile Jauberteau-Marchan Céline Hervieu Mireille Verdier Muriel Mathonnet |
| author_facet | Niki Christou Clément Auger Serge Battu Fabrice Lalloué Marie-Odile Jauberteau-Marchan Céline Hervieu Mireille Verdier Muriel Mathonnet |
| author_sort | Niki Christou |
| collection | DOAJ |
| description | (1) Background: Tumors of the peritoneal serosa are called peritoneal carcinosis. Their origin may be primary by primitive involvement of the peritoneum (peritoneal pseudomyxoma, peritoneal mesothelioma, etc.). This damage to the peritoneum can also be a consequence of the dissipation of cancers—in particular, digestive (stomach, pancreas, colorectal, appendix) and gynecological (ovaries) ones in the form of metastases. The aim of the treatment is a maximal reduction of the macroscopic disease called “cytoreduction” in combination with hyperthermic intra-abdominal chemotherapy to treat residual microscopic lesions. (2) Methods: In this narrative review, we fundamentally synthetize the evolution of this process over time and its impact on clinical applications. (3) Results: Over the last past decade, different evolutions concerning both delivery modes and conditions concerning hyperthermic intra-abdominal chemotherapy have been realized. (4) Conclusion: The final objective of these evolutions is the improvement of the global and recurrence-free survival of primary and secondary malignant peritoneal pathologies. However, more large randomized controlled trials are needed to demonstrate the efficacy of such treatments with the help of molecular biology and genetics. |
| first_indexed | 2024-03-10T13:13:52Z |
| format | Article |
| id | doaj.art-d068ff9b5bfb48b2bd23ff6e8d10fe36 |
| institution | Directory Open Access Journal |
| issn | 2079-7737 |
| language | English |
| last_indexed | 2024-03-10T13:13:52Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology |
| spelling | doaj.art-d068ff9b5bfb48b2bd23ff6e8d10fe362023-11-21T10:35:15ZengMDPI AGBiology2079-77372021-03-0110322510.3390/biology10030225Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future PerspectivesNiki Christou0Clément Auger1Serge Battu2Fabrice Lalloué3Marie-Odile Jauberteau-Marchan4Céline Hervieu5Mireille Verdier6Muriel Mathonnet7Service de Chirurgie Digestive, Endocrinienne et Générale, CHU de Limoges, Avenue Martin Luther King, 87042 Limoges CEDEX, FranceLaboratoire EA 3842, CAPtuR, Contrôle de l’Activation Cellulaire, Progression Tumorale et Résistance Thérapeutique, Faculté de Médecine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, FranceLaboratoire EA 3842, CAPtuR, Contrôle de l’Activation Cellulaire, Progression Tumorale et Résistance Thérapeutique, Faculté de Médecine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, FranceLaboratoire EA 3842, CAPtuR, Contrôle de l’Activation Cellulaire, Progression Tumorale et Résistance Thérapeutique, Faculté de Médecine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, FranceLaboratoire EA 3842, CAPtuR, Contrôle de l’Activation Cellulaire, Progression Tumorale et Résistance Thérapeutique, Faculté de Médecine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, FranceLaboratoire EA 3842, CAPtuR, Contrôle de l’Activation Cellulaire, Progression Tumorale et Résistance Thérapeutique, Faculté de Médecine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, FranceLaboratoire EA 3842, CAPtuR, Contrôle de l’Activation Cellulaire, Progression Tumorale et Résistance Thérapeutique, Faculté de Médecine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, FranceService de Chirurgie Digestive, Endocrinienne et Générale, CHU de Limoges, Avenue Martin Luther King, 87042 Limoges CEDEX, France(1) Background: Tumors of the peritoneal serosa are called peritoneal carcinosis. Their origin may be primary by primitive involvement of the peritoneum (peritoneal pseudomyxoma, peritoneal mesothelioma, etc.). This damage to the peritoneum can also be a consequence of the dissipation of cancers—in particular, digestive (stomach, pancreas, colorectal, appendix) and gynecological (ovaries) ones in the form of metastases. The aim of the treatment is a maximal reduction of the macroscopic disease called “cytoreduction” in combination with hyperthermic intra-abdominal chemotherapy to treat residual microscopic lesions. (2) Methods: In this narrative review, we fundamentally synthetize the evolution of this process over time and its impact on clinical applications. (3) Results: Over the last past decade, different evolutions concerning both delivery modes and conditions concerning hyperthermic intra-abdominal chemotherapy have been realized. (4) Conclusion: The final objective of these evolutions is the improvement of the global and recurrence-free survival of primary and secondary malignant peritoneal pathologies. However, more large randomized controlled trials are needed to demonstrate the efficacy of such treatments with the help of molecular biology and genetics.https://www.mdpi.com/2079-7737/10/3/225peritoneal carcinosishyperthermic intra-abdominal chemotherapycomplex chemotherapeutic agentsrecommendations |
| spellingShingle | Niki Christou Clément Auger Serge Battu Fabrice Lalloué Marie-Odile Jauberteau-Marchan Céline Hervieu Mireille Verdier Muriel Mathonnet Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives Biology peritoneal carcinosis hyperthermic intra-abdominal chemotherapy complex chemotherapeutic agents recommendations |
| title | Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives |
| title_full | Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives |
| title_fullStr | Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives |
| title_full_unstemmed | Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives |
| title_short | Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives |
| title_sort | intraperitoneal chemotherapy for peritoneal metastases technical innovations preclinical and clinical advances and future perspectives |
| topic | peritoneal carcinosis hyperthermic intra-abdominal chemotherapy complex chemotherapeutic agents recommendations |
| url | https://www.mdpi.com/2079-7737/10/3/225 |
| work_keys_str_mv | AT nikichristou intraperitonealchemotherapyforperitonealmetastasestechnicalinnovationspreclinicalandclinicaladvancesandfutureperspectives AT clementauger intraperitonealchemotherapyforperitonealmetastasestechnicalinnovationspreclinicalandclinicaladvancesandfutureperspectives AT sergebattu intraperitonealchemotherapyforperitonealmetastasestechnicalinnovationspreclinicalandclinicaladvancesandfutureperspectives AT fabricelalloue intraperitonealchemotherapyforperitonealmetastasestechnicalinnovationspreclinicalandclinicaladvancesandfutureperspectives AT marieodilejauberteaumarchan intraperitonealchemotherapyforperitonealmetastasestechnicalinnovationspreclinicalandclinicaladvancesandfutureperspectives AT celinehervieu intraperitonealchemotherapyforperitonealmetastasestechnicalinnovationspreclinicalandclinicaladvancesandfutureperspectives AT mireilleverdier intraperitonealchemotherapyforperitonealmetastasestechnicalinnovationspreclinicalandclinicaladvancesandfutureperspectives AT murielmathonnet intraperitonealchemotherapyforperitonealmetastasestechnicalinnovationspreclinicalandclinicaladvancesandfutureperspectives |